<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907828</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-0009</org_study_id>
    <nct_id>NCT01907828</nct_id>
  </id_info>
  <brief_title>A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence</brief_title>
  <acronym>RDN+AF</acronym>
  <official_title>A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post market clinical investigation is to complete preliminary evaluation
      on whether or not concomitant renal denervation with the EnligHTN™ Renal Denervation System
      and cardiac ablation will result in improved outcomes as compared to ablation alone in
      patients with uncontrolled hypertension being treated for Atrial Fibrillation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post market, prospective, multicenter, 2:1 randomized study of the EnligHTN™ Renal
      Denervation System in conjunction with atrial fibrillation ablation. Up to one hundred
      subjects with paroxysmal or persistent atrial fibrillation and uncontrolled hypertension will
      be enrolled in the study. All subjects will undergo cardiac ablation for the treatment of
      atrial fibrillation. Per the 2:1 randomization, a minimum of 50 or 2/3 of the total patient
      cohort will also undergo renal artery ablation. Subjects will be followed up to years (2)
      years post procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2014</start_date>
  <completion_date type="Actual">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">October 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Freedom From Atrial Fibrillation at 12 Month</measure>
    <time_frame>12 months</time_frame>
    <description>The freedom from atrial fibrillation was assessed based on electrocardiographic data during nine months following the blanking period including the one week recording coinciding with the 12 month follow-up visit (9 months following the 3 month blanking period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>7 days, 6 months, 12 months, and 24 months post procedure</time_frame>
    <description>Major adverse cardiac events (MACE) were summarized as a percentage based on number of subjects at baseline for each group (RDN+AF group = 39, AF group = 22).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Peri-procedural Events</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Peri-procedural events within 30 days post procedure were summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Renovascular Safety as Measured by New Renal Artery Stenosis or Aneurysm at the Site of Ablation</measure>
    <time_frame>6 months and 12 months post procedure</time_frame>
    <description>Renovascular safety (new renal artery stenosis or aneurysm) was summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Change Based on Estimated Glomerular Filtration Rate (eGFR) (Renal Denervation Group Only) at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Change Based on eGFR (Renal Denervation Group Only) at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of Atrial Fibrillation (AF) Based on Electrocardiographic Data up to 2 Years Following the Initial Cardiac Ablation Procedure.</measure>
    <time_frame>3 months, 6 months, 12 months, 24 months</time_frame>
    <description>Recurrence of AF was summarized as a percentage based on the number of subjects who underwent the procedure (RDN+AF group= 39, AF group=20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Office Systolic Blood Pressure &lt; 140 mmHg</measure>
    <time_frame>6 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Blood Pressure at 12 Months</measure>
    <time_frame>Baseline and 12 months post procedure</time_frame>
    <description>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 22, AF group=14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Blood Pressure at 24 Months</measure>
    <time_frame>Baseline and 24 months post procedure</time_frame>
    <description>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 17, AF group=12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Blood Pressure at 12 Months</measure>
    <time_frame>Baseline and 12 months post procedure</time_frame>
    <description>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 33, AF group=15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Blood Pressure at 24 Months</measure>
    <time_frame>Baseline and 24 months post procedure</time_frame>
    <description>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 29, AF group=16).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Cardiac ablation + renal artery ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal artery ablation with the EnligHTN™ Renal Denervation System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiac ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Artery Ablation</intervention_name>
    <description>Renal artery denervation using the EnligHTN™ Renal Denervation System</description>
    <arm_group_label>Cardiac ablation + renal artery ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Ablation</intervention_name>
    <description>Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer</description>
    <arm_group_label>Cardiac ablation</arm_group_label>
    <arm_group_label>Cardiac ablation + renal artery ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age at time of consent

          -  Subject must be able and willing to provide written informed consent

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Subject is a candidate for catheter ablation for the treatment of paroxysmal or
             persistent atrial fibrillation as per the hospital standard of care

          -  Subject has office Systolic Blood Pressure ≥ 140 mmHg at baseline visit

          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure &gt; 135 mmHg within 90
             days prior to procedure

          -  Subject has established hypertension (diagnosed ≥12 month prior to baseline) and is
             taking &gt;3 anti-hypertensive medications, including 1 diuretic

          -  Subject has been on a stable unchanged anti-hypertensive medication regimen for a
             minimum of 4 weeks prior to the ablation procedure

        Exclusion Criteria:

          -  Subject has long standing atrial fibrillation

          -  Subject has had a previous ablation for atrial fibrillation

          -  Subject has had a previous renal denervation procedure

          -  Subject has had a CABG procedure within the last 180 days (six months)

          -  Subject has a left atrial thrombus

          -  Subject has a contraindication to anticoagulation (i.e. heparin or warfarin)

          -  Subject has unstable angina

          -  Subject has had a myocardial infarction within the previous two months

          -  Subject has a left ventricular ejection fraction (LVEF) &lt;40% as determined by
             pre-procedure TTE

          -  Subject has significant renovascular abnormalities such as renal artery stenosis &gt; 30%

          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal
             stents, and/or abdominal aortic stent grafts

          -  Subject has hemodynamically significant valvular heart disease as determined by study
             investigator

          -  Subject has a life expectancy less than 12 months, as determined by the study
             investigator

          -  Subject is participating in another clinical study which has the potential to impact
             his/her hypertension or atrial fibrillation management
             (pharmaceutical/device/homeopathic)

          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate
             contraceptive methods

          -  Subject has active systemic infection

          -  Subject has renal arteries &lt; 4 mm in diameter

          -  Subject has an estimated GFR &lt;45 mL/min per 1.73 m2 using the Modification of Diet in
             Renal Disease (MDRD) formula

          -  Subject had a renal transplant or is awaiting a renal transplant

          -  Subject has blood clotting or bleeding abnormalities

          -  Subject has secondary arterial hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Piorkowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Dresden GmbH Universitätsklinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Dresden GmbH Universitätsklinik</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <results_first_submitted>September 5, 2019</results_first_submitted>
  <results_first_submitted_qc>May 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2020</results_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 4, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01907828/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01907828/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study enrollment was completed with a total of 61 participants randomized at 2 sites in Germany. The first and last participants were enrolled on May 12, 2014, and July 21, 2016, respectively.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
          <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
        </group>
        <group group_id="P2">
          <title>Cardiac Ablation (AF)</title>
          <description>Participants treated with cardiac ablation alone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Underwent Procedure</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="20">2 participants terminated early</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>1-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37">2 participants terminated early</participants>
                <participants group_id="P2" count="17">3 participants terminated early</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="36">1 participant terminated early</participants>
                <participants group_id="P2" count="16">1 participant terminated early</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>6-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35">1 participant terminated early</participants>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="34">1 participant terminated early</participants>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24-month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="32">2 participants terminated early</participants>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Exclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant refused 24-month follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant met exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
          <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
        </group>
        <group group_id="B2">
          <title>Cardiac Ablation (AF)</title>
          <description>Participants treated with cardiac ablation alone.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="7.9"/>
                    <measurement group_id="B2" value="63.0" spread="9.9"/>
                    <measurement group_id="B3" value="65.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.7" spread="10.1"/>
                    <measurement group_id="B2" value="173.6" spread="9.4"/>
                    <measurement group_id="B3" value="173.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.4" spread="17.9"/>
                    <measurement group_id="B2" value="93.7" spread="19.1"/>
                    <measurement group_id="B3" value="94.8" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="5.0"/>
                    <measurement group_id="B2" value="31.0" spread="5.4"/>
                    <measurement group_id="B3" value="31.6" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Office Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Office Systolic Blood Pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.0" spread="18.6"/>
                    <measurement group_id="B2" value="167.1" spread="18.5"/>
                    <measurement group_id="B3" value="163.9" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office Diastolic Blood Pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.5" spread="14.1"/>
                    <measurement group_id="B2" value="91.4" spread="10.6"/>
                    <measurement group_id="B3" value="88.9" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Office Heart Rate</title>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.3" spread="23.9"/>
                    <measurement group_id="B2" value="76.7" spread="19.5"/>
                    <measurement group_id="B3" value="79.7" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with a history of renal assessment prior to enrollment</title>
          <description>Renal artery imaging was performed using Computed Tomography (CT) or Magnetic Resonance (MR) angiogram within 90 days prior to enrollment. Non-contrast Magnetic Resonance Imaging (MRI) and doppler evaluation or ultrasound were also acceptable.
Renal artery evaluation data collected included but was not limited to:
Type of evaluation (CT, MR angiogram, non-contrast MRI, doppler)
Length of artery(s)
Diameter of artery(s)
Number of main renal arteries
Number of accessory renal arteries
Presence and percent of stenosis
Other abnormalities</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class of Cardiac Disease</title>
          <description>NYHA assessment was evaluated based on limitation of physical activity using the following definitions:
Class I - Patients with cardiac disease but resulting in no limitation of physical activity.
Class II- Patients with cardiac disease resulting in slight limitation of physical activity.
Class III - Patients with cardiac disease resulting in marked limitation of physical activity.
Class IV- Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Class I was considered to have better outcomes and Class IV with worse outcomes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Myocardial Infarction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valvular Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrhythmia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiomyopathy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological events/Dysfunction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smokers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant Alcohol Intake</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obstructive Sleep Apnea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Additional Medical History</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From Atrial Fibrillation at 12 Month</title>
        <description>The freedom from atrial fibrillation was assessed based on electrocardiographic data during nine months following the blanking period including the one week recording coinciding with the 12 month follow-up visit (9 months following the 3 month blanking period).</description>
        <time_frame>12 months</time_frame>
        <population>Data not collected from all participants: data were available for only 28 participants in the RDN+AF group, and 12 participants in the AF group</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Atrial Fibrillation at 12 Month</title>
          <description>The freedom from atrial fibrillation was assessed based on electrocardiographic data during nine months following the blanking period including the one week recording coinciding with the 12 month follow-up visit (9 months following the 3 month blanking period).</description>
          <population>Data not collected from all participants: data were available for only 28 participants in the RDN+AF group, and 12 participants in the AF group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier analysis performed to provide freedom from atrial fibrillation rates at one year for each randomization arm using date of ablation procedure to date of first event.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <description>Major adverse cardiac events (MACE) were summarized as a percentage based on number of subjects at baseline for each group (RDN+AF group = 39, AF group = 22).</description>
        <time_frame>7 days, 6 months, 12 months, and 24 months post procedure</time_frame>
        <population>For each group, the outcome measure was analyzed in participants randomized at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE)</title>
          <description>Major adverse cardiac events (MACE) were summarized as a percentage based on number of subjects at baseline for each group (RDN+AF group = 39, AF group = 22).</description>
          <population>For each group, the outcome measure was analyzed in participants randomized at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE within 7 days of procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE within 6 months of procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE within 12 months of procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE within 24 months of procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience Peri-procedural Events</title>
        <description>Peri-procedural events within 30 days post procedure were summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22)</description>
        <time_frame>30 days post procedure</time_frame>
        <population>Peri-procedural events within 30 days post procedure were summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Peri-procedural Events</title>
          <description>Peri-procedural events within 30 days post procedure were summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22)</description>
          <population>Peri-procedural events within 30 days post procedure were summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac Arrest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pericardial Effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal Atrial Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pericardial Tamponade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Pseudoaneurysm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Air Embolus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasospasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Renovascular Safety as Measured by New Renal Artery Stenosis or Aneurysm at the Site of Ablation</title>
        <description>Renovascular safety (new renal artery stenosis or aneurysm) was summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</description>
        <time_frame>6 months and 12 months post procedure</time_frame>
        <population>Renovascular safety (new renal artery stenosis or aneurysm) was summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Renovascular Safety as Measured by New Renal Artery Stenosis or Aneurysm at the Site of Ablation</title>
          <description>Renovascular safety (new renal artery stenosis or aneurysm) was summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</description>
          <population>Renovascular safety (new renal artery stenosis or aneurysm) was summarized as a percentage based on the number of subjects at baseline for each group (RDN+AF group= 39, AF group=22).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VASC Pseudoaneurysm at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASC Pseudoaneurysm at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Artery Stenosis at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Artery Stenosis at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Change Based on Estimated Glomerular Filtration Rate (eGFR) (Renal Denervation Group Only) at 6 Months</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>eGFR change from baseline was summarized based on subjects with available data at both time points (RDN+AF group = 32)</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Change Based on Estimated Glomerular Filtration Rate (eGFR) (Renal Denervation Group Only) at 6 Months</title>
          <population>eGFR change from baseline was summarized based on subjects with available data at both time points (RDN+AF group = 32)</population>
          <units>mL/min per 1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2766</p_value>
            <method>Paired Student's t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Change Based on eGFR (Renal Denervation Group Only) at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>eGFR change from baseline was summarized based on subjects with available data at both time points (RDN+AF group = 33)</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Change Based on eGFR (Renal Denervation Group Only) at 12 Months</title>
          <population>eGFR change from baseline was summarized based on subjects with available data at both time points (RDN+AF group = 33)</population>
          <units>mL/min per 1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7663</p_value>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence of Atrial Fibrillation (AF) Based on Electrocardiographic Data up to 2 Years Following the Initial Cardiac Ablation Procedure.</title>
        <description>Recurrence of AF was summarized as a percentage based on the number of subjects who underwent the procedure (RDN+AF group= 39, AF group=20)</description>
        <time_frame>3 months, 6 months, 12 months, 24 months</time_frame>
        <population>For each group, the outcome measure was analyzed in participants who underwent the procedure (RDN+AF group= 39, AF group=20)</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of Atrial Fibrillation (AF) Based on Electrocardiographic Data up to 2 Years Following the Initial Cardiac Ablation Procedure.</title>
          <description>Recurrence of AF was summarized as a percentage based on the number of subjects who underwent the procedure (RDN+AF group= 39, AF group=20)</description>
          <population>For each group, the outcome measure was analyzed in participants who underwent the procedure (RDN+AF group= 39, AF group=20)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrial Fibrillation recurrence within 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Fibrillation recurrence within 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Fibrillation recurrence within 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial Fibrillation recurrence within 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Office Systolic Blood Pressure &lt; 140 mmHg</title>
        <time_frame>6 months post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Office Systolic Blood Pressure &lt; 140 mmHg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ambulatory Blood Pressure at 12 Months</title>
        <description>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 22, AF group=14)</description>
        <time_frame>Baseline and 12 months post procedure</time_frame>
        <population>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 22, AF group=14)</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ambulatory Blood Pressure at 12 Months</title>
          <description>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 22, AF group=14)</description>
          <population>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 22, AF group=14)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-Hour Ambulatory Systolic Blood Pressure (ASBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="15.2"/>
                    <measurement group_id="O2" value="-3.1" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Hour Ambulatory Diastolic Blood Pressure (ADBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="7.4"/>
                    <measurement group_id="O2" value="-8.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in ASBP at 12 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0849</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.86</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.61</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in ADBP at 12 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.82</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.12</ci_lower_limit>
            <ci_upper_limit>-2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ASBP at 12 months.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5599</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.16</ci_lower_limit>
            <ci_upper_limit>8.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ADBP at 12 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.87</ci_lower_limit>
            <ci_upper_limit>-2.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ambulatory Blood Pressure at 24 Months</title>
        <description>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 17, AF group=12)</description>
        <time_frame>Baseline and 24 months post procedure</time_frame>
        <population>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 17, AF group=12)</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ambulatory Blood Pressure at 24 Months</title>
          <description>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 17, AF group=12)</description>
          <population>Change in Ambulatory Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 17, AF group=12)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-Hour Ambulatory Systolic Blood Pressure (ASBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="14.8"/>
                    <measurement group_id="O2" value="-8.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Hour Ambulatory Diastolic Blood Pressure (ADBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="6.1"/>
                    <measurement group_id="O2" value="-10.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in ASBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1326</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.71</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.34</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in ADBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.94</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.06</ci_lower_limit>
            <ci_upper_limit>-3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ASBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0354</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.58</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.47</ci_lower_limit>
            <ci_upper_limit>-0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ADBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.33</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.75</ci_lower_limit>
            <ci_upper_limit>-4.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Blood Pressure at 12 Months</title>
        <description>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 33, AF group=15)</description>
        <time_frame>Baseline and 12 months post procedure</time_frame>
        <population>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 33, AF group=15)</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Blood Pressure at 12 Months</title>
          <description>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 33, AF group=15)</description>
          <population>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 33, AF group=15)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Office Systolic Blood Pressure (OSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="24.4"/>
                    <measurement group_id="O2" value="2.0" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Office Diastolic Blood Pressure (ODBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="11.8"/>
                    <measurement group_id="O2" value="-5.4" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in OSBP at 12 months.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5399</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>11.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Office Diastolic Blood Pressure (ODBP) at 12 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8489</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Change in Office Systolic Blood Pressure (OSBP) at 12 months.</non_inferiority_desc>
            <p_value>0.7999</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>30.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ODBP at 12 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2076</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Blood Pressure at 24 Months</title>
        <description>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 29, AF group=16).</description>
        <time_frame>Baseline and 24 months post procedure</time_frame>
        <population>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 29, AF group=16).</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
            <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Ablation (AF)</title>
            <description>Participants treated with cardiac ablation alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Blood Pressure at 24 Months</title>
          <description>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 29, AF group=16).</description>
          <population>Change in Office Blood Pressure was summarized based on subjects with available data at both time points (RDN+AF group= 29, AF group=16).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Office Systolic Blood Pressure (OSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="22.3"/>
                    <measurement group_id="O2" value="7.4" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Office Diastolic Blood Pressure (ODBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="11.0"/>
                    <measurement group_id="O2" value="-3.0" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in OSBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8820</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in ODBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8019</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in OSBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2177</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ODBP at 24 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4502</p_value>
            <method>Paired Student's t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Renal Artery Ablation + Cardiac Ablation (RDN+AF)</title>
          <description>Participants treated with renal artery ablation using the EnligHTN System and cardiac ablation.</description>
        </group>
        <group group_id="E2">
          <title>Cardiac Ablation (AF)</title>
          <description>Participants treated with cardiac ablation alone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Paroxysmal Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paroxysmal Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pericardial Tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASC Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Air Embolus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>VASC Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rebecca Maslow, MA, Clinical Project Manager</name_or_title>
      <organization>Abbott</organization>
      <phone>+1 651-756-5564</phone>
      <email>rebecca.maslow@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

